Skip to content
drillr.ai

ANIP

ANI Pharmaceuticals, Inc.

NASDAQ · USHealthcareDrug Manufacturers - Specialty & Generic
$77.72-1.87%

Price as of Jul 20, 2026

ANIP news

ANI Pharmaceuticals, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter

    * Trial court denied Company’s motion for a new trial and judgment as a matter of law for unjust enrichment * ANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover the value of the assets it sold to CG Oncology in 2010 PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Judge Sheldon K. Rennie, on July 16, 2026, denied ANI’s post-trial motions for a new trial and judgment as a

    Globe Newswire ·

  2. ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis

    * Trial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline CST with statistical significance at 6 months * The most common adverse events reported were consistent with prior trials of fluocinolone acetonide intravitreal implant 0.18 mg * Study evaluated patients with chronic NIU-PS in the U.S. Most patients in the study were treated by retina specialists. * Full results to be presented at an upcoming medical meeting PRINCETON, N.J., July

    Globe Newswire ·

  3. ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

    PRINCETON, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference as follows: Date: Wednesday, June 3, 2026

    Globe Newswire ·

  4. ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance

    * Quarterly net revenues of $237.5 million, an increase of 20.5% year-over-year * Purified Cortrophin(®) Gel net revenues of $75.1 million, an increase of 42.1% year-over-year * Quarterly GAAP net income available to common shareholders of $29.5 million; Quarterly adjusted non-GAAP EBITDA of $63.0 million, an increase of 24.1% year-over-year * Diluted GAAP income per share of $1.28 and adjusted non-GAAP diluted earnings per share of $2.05 * Raised 2026 total net revenue guidance to $1,080 millio

    Globe Newswire ·

  5. ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET

    PRINCETON, N.J., April 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its first quarter 2026 financial results on Friday, May 8, 2026, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a webcast and conference call to discuss the results. To view the

    Globe Newswire ·

  6. ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity

    PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pimozide Tablets 1 mg and 2 mg. ANI’s Pimozide Tablets is the generic version of the reference listed drug (RLD) Orap(®). "We are proud to announce the launch of Pimozide Tablets with 180-Day CGT exclusivity. We are excited to bring limited competition products to market and continue to provide generic alternatives to our customers and patients,” stated

    Globe Newswire ·

  7. ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules

    PRINCETON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Carbamazepine Extended-Release Capsules, 100 mg, 200 mg and 300 mg. ANI’s Carbamazepine Extended-Release Capsules are the generic version of the reference listed drug (RLD) Carbatrol(®). "Continuing to strengthen our Generics portfolio through strategic product launches remains a key priority for us,” stated Nikhil Lalwani, President and Chief Executive

    Globe Newswire ·

  8. ANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet

    PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched Isosorbide Mononitrate Tablet USP, 10 mg and 20 mg. ANI’s Isosorbide Mononitrate Tablet USP is the generic version of the reference listed drug (RLD) Monoket(®). “We are pleased to announce FDA approval and launch of Isos

    Globe Newswire ·

  9. ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology

    PRINCETON, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced publication of the results from the NEW DAY clinical trial involving ILUVIEN(®) (fluocinolone acetonide intravitreal implant), 0.19 mg (ILUVIEN) for use in appropriate patients with diabetic macular edema in Ophthalmology, the journal of the American Academy of Ophthalmology. The company previously announced results from the NEW DAY trial in July 2025. ILUVIEN is a co

    Globe Newswire ·

  10. ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance

    * Record quarterly and full year net revenues of $247.1 million and $883.4 million, up 29.6% and 43.8% year-over-year, respectively * Total Rare Disease quarterly and full year net revenue of $131.3 million and $422.6 million, up 50.8% and 84.1% year-over-year, respectively * Quarterly and full year Purified Cortrophin(®) Gel net revenues of $111.4 million and $347.8 million, up 87.6% and 75.6% year-over-year, respectively * Quarterly and full year ILUVIEN(®) and YUTIQ(®) net revenues of $19.8 m

    Globe Newswire ·